Scholarlink

Background <p>The pace-and-ablate strategy is second-line therapy to obtain rate control in patients with persistent symptomatic atrial fibrillation (AF) when other treatment options fail. This study aims to evaluate long-term effects on clinical outcomes following pace-and-ablate strategy in AF patients.</p> Methods <p>This retrospective study includes patients who underwent successful pacemaker implantation (right ventricular pacing (RVP) or cardiac re-synchronization therapy (CRT)) followed by atrioventricular node ablation (AVNA) between 2010 and 2020. Patients were treated according to the prevailing guidelines. The primary endpoint was a composite of all-cause mortality and heart failure hospitalization (HFH). Secondary endpoints were individual outcomes of all-cause mortality, HFH, and left-ventricular ejection fraction (LVEF) change.</p> Results <p>Two hundred ninety-eight patients were included, 162 undergoing RVP, and 136 receiving CRT, with a median follow-up of 5.8 years [4.1–8.0]. The primary endpoint occured in 47% of the RVP group and 49% of the CRT group (<i>p</i> = 0.206). All-cause mortality occurred in 36% of the RVP group and in 45% of the CRT group (<i>p</i> = 0.005). HFH occurred in 22% of the RVP group and in 15% of the CRT group (<i>p</i> = 0.328), with 17(10%) upgrades to CRT in the RVP group. Median LVEF in the RVP group remained stable (56% [49–60] to 53% [43–57]; <i>p</i> = 0.081), while it improved in the CRT group (31% [22–38] to 43% [32–51]; <i>p</i> &lt; 0.001).</p> Conclusion <p>Mortality and HFH in patients with AF managed through a pace-and-ablate strategy are high. Reassuringly, LVEF deterioration requiring upgrade to CRT is uncommon in patients undergoing RVP with normal baseline LVEF before AVNA. CRT improves LVEF in patients with reduced LVEF before AVNA.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term outcomes of pace-and-ablate strategy in patients with atrial fibrillation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月7日

查看全文
  • Johan van Koll,
  • Madelon D. E. A. Engels,
  • Jesse H. J. Rijks,
  • Madelon Salari,
  • Jelle Luijten,
  • Joost Lumens,
  • Vanessa P. M. van Empel,
  • Sjoerd W. Westra,
  • Antonius M. W. van Stipdonk,
  • Theo A. R. Lankveld,
  • Sevasti M. Chaldoupi,
  • Jacqueline Joza,
  • Rypko J. Beukema,
  • Justin G. L. M. Luermans,
  • Dominik K. Linz,
  • Kevin Vernooy

摘要

Background

The pace-and-ablate strategy is second-line therapy to obtain rate control in patients with persistent symptomatic atrial fibrillation (AF) when other treatment options fail. This study aims to evaluate long-term effects on clinical outcomes following pace-and-ablate strategy in AF patients.

Methods

This retrospective study includes patients who underwent successful pacemaker implantation (right ventricular pacing (RVP) or cardiac re-synchronization therapy (CRT)) followed by atrioventricular node ablation (AVNA) between 2010 and 2020. Patients were treated according to the prevailing guidelines. The primary endpoint was a composite of all-cause mortality and heart failure hospitalization (HFH). Secondary endpoints were individual outcomes of all-cause mortality, HFH, and left-ventricular ejection fraction (LVEF) change.

Results

Two hundred ninety-eight patients were included, 162 undergoing RVP, and 136 receiving CRT, with a median follow-up of 5.8 years [4.1–8.0]. The primary endpoint occured in 47% of the RVP group and 49% of the CRT group (p = 0.206). All-cause mortality occurred in 36% of the RVP group and in 45% of the CRT group (p = 0.005). HFH occurred in 22% of the RVP group and in 15% of the CRT group (p = 0.328), with 17(10%) upgrades to CRT in the RVP group. Median LVEF in the RVP group remained stable (56% [49–60] to 53% [43–57]; p = 0.081), while it improved in the CRT group (31% [22–38] to 43% [32–51]; p < 0.001).

Conclusion

Mortality and HFH in patients with AF managed through a pace-and-ablate strategy are high. Reassuringly, LVEF deterioration requiring upgrade to CRT is uncommon in patients undergoing RVP with normal baseline LVEF before AVNA. CRT improves LVEF in patients with reduced LVEF before AVNA.

Graphical Abstract